


GSK461364

| | | | |
|---------------------------|--|-------|---------|
| Cat. No.: | HY-50877 | | |
| CAS No.: | 929095-18-1 | | |
| Molecular Formula: | C ₂₇ H ₂₈ F ₃ N ₅ O ₂ S | | |
| Molecular Weight: | 543.6 | | |
| Target: | Polo-like Kinase (PLK) | | |
| Pathway: | Cell Cycle/DNA Damage | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 2 years |
| | | -20°C | 1 year |



SOLVENT & SOLUBILITY

| | | | | | | |
|---|--|--------------------------|-----------|-----------|-----------|------------|
| In Vitro | DMSO : 50 mg/mL (91.98 mM; Need ultrasonic) | | | | | |
| | | Solvent Concentration | Mass | 1 mg | 5 mg | 10 mg |
| | Preparing Stock Solutions | 1 mM | | 1.8396 mL | 9.1979 mL | 18.3959 mL |
| | | 5 mM | | 0.3679 mL | 1.8396 mL | 3.6792 mL |
| 10 mM | | | 0.1840 mL | 0.9198 mL | 1.8396 mL | |
| Please refer to the solubility information to select the appropriate solvent. | | | | | | |
| In Vivo | <ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.60 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (4.60 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.60 mM); Clear solution | | | | | |

BIOLOGICAL ACTIVITY

| | |
|-------------------------------------|---|
| Description | GSK461364 is a selective, reversible and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with a K _i value of 2.2 nM. |
| IC₅₀ & Target | PLK1 2.2 nM (K _i) |
| In Vitro | GSK461364 is a potent, selective, and reversible ATP-competitive Plk1 inhibitor (K _i , 2.2 nM) with at least 390-fold greater selectivity for Plk1 than for Plk2 and Plk3 and 1,000-fold greater selectivity than for a panel of 48 other kinases ^[1] . GSK461364 |

(GSK461364A, 250 nM) inhibiting plk1 causes prolonged mitotic delay, aberrant mitotic exit, and p53 activation in A549 and PL45 cells. Knockdown of p53 significantly enhances the sensitivity of the cells to GSK461364A (30 or 300 nM) in preventing outgrowth in A549 and NCI-H460 cells, compared with cells with nonsilencing control siRNA^[2]. GSK461364 can inhibit cell growth of most proliferating cancer cell lines, and suppresses 89% of cancer cell line (66 of 74 lines) proliferation, with a GI₅₀ (concentration required to inhibit 50% cell growth) of ≤ 100 nM. GSK461364 (GSK461364A, >20 nM) blocks cells in G2-M phase with reduction of cells in G1 phase of A549 lung carcinoma line. GSK461364 (10-250 nM) blocks cells in G2 and M phases of the cell cycle and causes M-phase caspase-3/caspase-7 activation in cancer cells^[3]. GSK461364 (0.5-2 μ M) decreases level of PLK1 and pCDC25C, and causes a dose- and time-dependent increase in pHisH3, an indicator of mitotic arrest in OS cell lines^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

GSK461364 (50 mg/kg) exhibits various degrees of tumor growth delay (TGD) in multiple xenograft tumor models by i.p. one dose every 2 days repeated twelve times (q2d \times 12)^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Kinase Assay^[3]

Kinase reactions are performed in a final assay volume of 10 μ L using the Z'-Lyte Assay kit (Ser/Thr peptide 16). Briefly, reactions contained 50 mM HEPES (pH 7.5), 10 mM MgCl₂, 1 mM EGTA, 1 mM DTT, 0.01% Brij 35, 0.01 mg/mL casein, 200 μ M ATP, 200 μ M Polo Box peptide (NH₂-MAGPMQS[pT]PLNGAKK-OH), and 6 nM recombinant Plk1 (H6-tev-PLK 1-603). Plk1 is preincubated for 60 min in the presence or absence of 0 to 1,000 nM GSK461364. Reactions are then initiated by the addition of 2 μ M peptide. After 15 min at 23°C, reactions are quenched and processed according to the Z'-Lyte protocol and read on a plate reader. Raw fluorescence values are converted to concentration of product formed using substrate and product standards. IC₅₀ values are determined using a two-parameter fit (Hill coefficient and IC₅₀) using GraFit software. Because the potency of inhibition for GSK461364 is observed to vary as a function of the ATP concentration in a manner consistent with an ATP-competitive mode of inhibition, an upper limit for the K_i^{*_{ATP}} for GSK461364 is determined by applying the Cheng-Prusoff relationship for a competitive inhibitor (ATP K_m^{*_{ATP}}=16 μ M) to the IC₅₀ value obtained with 60 min preincubation of GSK461364.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[3]

Cell lines grow in the recommended media at 37°C, 5% CO₂ in a humidified incubator. Cells are plated in triplicate 96-well microtiter plates at 1,000 cells per well in culture media. GSK461364 (GSK461364A) dissolved in DMSO or negative control (0.1% DMSO) are added the following day, and one plate is harvested with 50 μ L of CellTiter-Glo for a time 0 (T=0) measurement.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]

Cells are implanted in Nude mice and grown as tumor xenografts. Dosing began when tumors achieve appr 100 mm³. GSK461364 (GSK461364A) or the vehicle [4% DMA/Cremaphore (50:50), pH 5.6] is given i.p. to mice every 2 d (q2d \times 6, q2d \times 12) or every 4 d (q4d \times 3) at nominal dose levels of 25, 50, and 100 mg/kg/dose. Results are reported as median tumor volume for n=7 to 8 mice. Paclitaxel (30 mg/kg i.v.; q4d \times 3) is used as a positive control for comparison. Tumors are measured thrice a week with Vernier calipers, and tumor volume is calculated from two-dimensional measurements using an equation approximating the volume of a prolate ellipsoid [tumor volume mm³=(length \times width²) \times 0.5]. The maximum tolerated dose is defined as the highest dose that produces $>20\%$ mortality or $>20\%$ weight loss (appr 4 g). Antitumor activity is defined as tumor growth delay (TGD), partial regression (PR), or complete regression (CR). TGD represents the time differential between the treated and control tumors to reach a predetermined tumor volume of 1,000 mm³. PR is defined as a decrease in an individual tumor volume to one-half the initial starting volume for at least 1 wk (three consecutive measurements). CR is defined as a decrease in an individual tumor volume to <13 mm³ for at least 1 wk.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
- Mol Cell. 2022 May 25;S1097-2765(22)00443-9.
- Sci Adv. 2023 Jan 6;9(1):eade1694.
- Theranostics. 2022; 12(8): 3911-3927.
- Eur J Cancer. 2013 Sep;49(14):3020-8.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Olmos D, et al. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res. 2011 May 15;17(10):3420-30.
- [2]. Degenhardt Y, et al. Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability. Mol Cancer Ther. 2010 Jul;9(7):2079-89
- [3]. Gilmartin AG, et al. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res. 2009 Sep 1;69(17):6969-77.
- [4]. Chou YS, et al. Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel. Int J Oncol. 2016 Mar;48(3):1187-94.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA